Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

NextEdge Admin

31 Oct 2024

2 min 40 sec

Telo Genomics Corp. , a biotech leader in telomere-based diagnostic technology, has extended its collaboration with Mayo Clinic, Minnesota, to advance its innovative prognostic tests for multiple myeloma (MM) patients. The partnership, initiated in 2020, initially focused on developing and validating TeloViewSMM, a test for patients with smoldering multiple myeloma (SMM), which is a precursor stage of MM. The TeloViewSMM test stratifies SMM patients by risk of progression to active MM, allowing high-risk patients to seek timely treatment and low-risk patients to avoid unnecessary therapies. A non-invasive blood-based test, TeloViewSMM is now an approved Laboratory Developed Test (LDT) on Telo’s CAP/CLIA and ISO 15189 accredited testing menu, with a projected market of over 500,000 tests per year.

The amended agreement adds Mayo Clinic’s participation in Telo's SMART (Physician Experience Program), using TeloViewSMM for real-world clinical application. The expansion also includes validation of TeloViewNDMM, a test designed for newly diagnosed MM (NDMM) patients, to assess the likelihood of relapse within a year while on first-line therapy. TeloViewNDMM addresses a critical clinical need, as over 50% of NDMM patients relapse within the first 12 months, with treatment costs ranging from $100,000 to $150,000 per year. By identifying patients at high risk of relapse, TeloViewNDMM enables physicians to adjust therapies preemptively, reducing the likelihood of relapse and associated costs.

With approximately 35,000 NDMM patients in the U.S. annually and 180,000 individuals living with MM, Telo’s tests present a total addressable market exceeding 800,000 tests per year. This extended partnership marks a significant step in Telo’s commercialization pathway, with potential to improve patient outcomes while addressing the economic burden of MM treatment.